Combination therapy with both anti-VEGF and laser for ROP has been evaluated in a few studies, which suggest that combination therapy may decrease the rate of ROP recurrence, as demonstrated in anti-VEGF monotherapy, with later use of laser therapy post-anti-VEGF injection associated with less myopic outcomes [138,139,140]. The gene discussed is VEGFA; the disease is retinopathy of prematurity.